A British pharma giant just posted numbers that made investors forget it's been a rough year.
AstraZeneca shares jumped as much as 2% on Monday.
The reason? Cancer drugs are printing money.
And the company just doubled down on a bet that sounds almost too big to believe: $80 billion in annual revenue by 2030.
Let's break down what actually happened.
Adjusted earnings per share hit $2.63 — up 21% year-on-year.
Total quarterly revenue climbed to $15.38 billion.
Not bad for a stock that was still down over 5% for the year before Monday's pop.
Everyone talks about AI stocks moving markets.
Meanwhile, two cancer drugs just moved a $200 billion pharma company.
That's not incremental growth. That's a portfolio hitting its stride.
Here's the part CEO Pascal Soriot didn't sugarcoat.
The Wainua cardiology trial should have worked. It didn't deliver the expected benefit when paired with a stabilizer therapy.
His response was almost philosophical:
"Biology is biology — it doesn't always deliver what you expect."
Ultomiris also disappointed in a rare blood disorder study.
Science doesn't grade on a curve. Even $2.63 EPS quarters come with setbacks buried inside them.
While cancer pays the bills today, AstraZeneca is eyeing the world's hottest drug category.
Its experimental oral obesity pill helped patients lose up to 11.8% of their body weight in trials.
That's squarely in the same weight class as therapies from Eli Lilly and Novo Nordisk — the two companies currently owning this market.
AstraZeneca's plan isn't to out-muscle them alone. It's to combine the pill with other treatments and carve out its own lane.
CFO Aradhana Sarin called AstraZeneca's long-term growth potential "one of its most overlooked strengths."
Translation: the market is still pricing this like a steady pharma stock.
But between cancer dominance, an obesity pill in the wings, and a $5 billion COPD bet in tozorakimab, this looks less like steady growth.
It looks like a company quietly building three separate blockbuster futures at once.
That's all for now!
